Solid microparticles based on chitosan or methyl-β-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate

Journal of Controlled Release

Volumn 201, Issue , 2015, Pages 68-77

  Rassu, Giovanna ^a   Soddu, Elena ^a   Cossu, Massimo ^a   Brundu, Antonio ^a   Cerri, Guido ^a   Marchetti, Nicola ^b   Ferraro, Luca ^b   Regan, Raymond F ^c   Giunchedi, Paolo ^a   Gavini, Elisabetta ^a   Dalpiaz, Alessandro ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chitosan chloride; Deferoxamine mesylate; Methyl cyclodextrin; Nasal formulations; Nose to brain transport; Pharmacokinetic studies

Indexed keywords

AMINES; BIOCHEMISTRY; CHITIN; CHITOSAN; CHLORINE COMPOUNDS; CYCLODEXTRINS; DRUG DELIVERY; DRUG PRODUCTS; MONOLAYERS;

AERODYNAMIC DIAMETERS; BRAIN TRANSPORT; CEREBRO SPINAL FLUIDS; DEFEROXAMINE MESYLATE; NASAL ADMINISTRATION; NASAL FORMULATIONS; PHARMACOKINETIC STUDIES; SOLID MICROPARTICLES;

CEREBROSPINAL FLUID;

CHITOSAN; DEFEROXAMINE MESYLATE; METHYL BETA CYCLODEXTRIN; MICROSPHERE; WATER; ARTIFICIAL MEMBRANE; BETA CYCLODEXTRIN DERIVATIVE; DEFEROXAMINE; DRUG CARRIER; METHYL-BETA-CYCLODEXTRIN; SIDEROPHORE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSPORT; FREEZE DRYING; HUMAN; HUMAN CELL; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROENCAPSULATION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PC12 CELL LINE; POWDER; PRIORITY JOURNAL; RAT; SPRAY DRYING; SWINE; WATER TRANSPORT; WISTAR RAT; ANIMAL; ARTIFICIAL MEMBRANE; BRAIN; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; PERMEABILITY; PIG; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL TRANSPORT; BRAIN; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DEFEROXAMINE; DRUG CARRIERS; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MICROSPHERES; NASAL MUCOSA; PERMEABILITY; RATS, WISTAR; SIDEROPHORES; SWINE;

EID: 84921776454     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.01.025     Document Type: Article

References (54)

1. V. Cullen, M. Lindfors, J. Ng, A. Paetau, E. Swinton, P. Kolodziej, H. Boston, P. Saftig, J. Woulfe, M.B. Feany, L. Myllykangas, M.G. Schlossmacher, and J. Tyynela Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo Mol. Brain 2 2009
2. E. Poggiali, E. Cassinerio, L. Zanaboni, and M.D. Cappellini An update on iron chelation therapy Blood Transfus. 10 2012 411 422
3. Y. Hua, R.F. Keep, J.T. Hoff, and G. Xi Deferoxamine therapy for intracerebral haemorrhage Acta Neurochir. Suppl. 105 2008 3 6
4. High-Dose Deferoxamine in Intracerebral Hemorrhage (HI-DEF) Available at: https://clinicaltrials.gov/ct2/show/NCT01662895?term=deferoxamine&rank=2 (Accessed on 5 december 2014)
5. H.D. Rosas, Y.I. Chen, G. Doros, D.H. Salat, N.K. Chen, K.K. Kwong, A. Bush, J. Fox, and S.M. Hersch Alterations in brain transition metals in Huntington disease: an evolving and intricate story Arch. Neurol. 69 2012 887 893
6. J. Chen, E. Marks, B. Lai, Z. Zhang, J.A. Duce, L.Q. Lam, I. Volitakis, A.I. Bush, S. Hersch, and J.H. Fox Iron accumulates in Huntington's disease neurons: protection by deferoxamine PLoS One 8 2013 e77023
7. T. Rival, R.M. Page, D.S. Chandraratna, T.J. Sendall, E. Ryder, B. Liu, H. Lewis, T. Rosahl, R. Hider, L.M. Camargo, M.S. Shearman, D.C. Crowther, and D.A. Lomas Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease Eur. J. Neurosci. 29 2009 1335 1347
8. C. Guo, T. Wang, W. Zheng, Z.-Y. Shan, W.-P. Teng, and Z.-Y. Wang Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease Neurobiol. Aging 34 2013 562 575
9. J.M. Fine, A.C. Forsberg, D.B. Renner, K.A. Faltesek, K.G. Mohan, J.C. Wong, L.C. Arneson, J.M. Crow, W.H. Frey II, and L.R. Hanson Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinsons disease Brain Res. 1574 2014 96 104
10. P.G. Mastroberardino, E.K. Hoffman, M.P. Horowitz, R. Betarbet, G. Taylor, D. Cheng, H.M. Na, C.A. Gutekunst, M. Gearing, J.Q. Trojanowski, M. Anderson, C.T. Chu, J. Peng, and J.T. Greenamyre A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease Neurobiol. Dis. 34 2009 417 431
11. F. Febbraro, K.J. Andersen, V. Sanchez-Guajardo, N. Tentillier, and M. Romero-Ramos Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model Exp. Neurol. 247 2013 45 58
12. S.Y. Jeong, K.I. Rathore, K. Schulz, P. Ponka, P. Arosio, and S. David Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis J. Neurosci. 29 2009 610 619
13. A. Singh, A.O. Isaac, X. Luo, M.L. Mohan, M.L. Cohen, F. Chen, Q. Kong, J. Bartz, and N. Singh Abnormal brain iron homeostasis in human and animal prion disorders PLoS Pathog. 5 2009 e1000336
14. A.R. Curtis, C. Fey, C.M. Morris, L.A. Bindoff, P.G. Ince, P.F. Chinnery, A. Coulthard, M.J. Jackson, A.P. Jackson, D.P. McHale, D. Hay, W.A. Barker, A.F. Markham, D. Bates, A. Curtis, and J. Burn Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease Nat. Genet. 28 2001 350 354
15. M. Selim, S. Yeatts, J.N. Goldstein, J. Gomes, S. Greenberg, L.B. Morgenstern, G. Schlaug, M. Torbey, B. Waldman, G. Xi, and Y. Palesch Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage Stroke 42 2011 3067 3074
16. M.H. Selim, and R.R. Ratan The role of iron neurotoxicity in ischemic stroke Ageing Res. Rev. 3 2004 345 353
17. L.R. Hanson, A. Roeytenberg, P.M. Martinez, V.G. Coppes, D.C. Sweet, R.J. Rao, D.L. Marti, J.D. Hoekman, R.B. Matthews, W.H. Frey II, and S.S. Panter Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke J. Pharmacol. Exp. Ther. 330 2009 679 686
18. K.J. Weigel, S.G. Lynch, and S.M. LeVine Iron chelation and multiple sclerosis ASN Neuro 6 2014 e00136
19. C. Dinc, A.C. Iplikcioglu, C. Atabey, A. Eroglu, K. Topuz, O. Ipcioglu, and D. Demirel Comparison of deferoxamine and methylprednisolone protective effect of pharmacological agents on lipid peroxidation in spinal cord injury in rats Spine 38 2013 E1649 E1655
20. C. Palmer, R.L. Roberts, and C. Bero DFX post treatment reduces ischemic brain injury in neonatal rats Stroke 25 1994 1039 1045
21. L. Zhang, R. Hu, M. Li, F. Li, H. Meng, G. Zhu, J. Lin, and H. Feng Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury Neurol. Sci. 34 2013 639 645
22. D.B. Shachar, N. Kahana, V. Kampel, A. Warshawsky, and M.B.H. Youdim Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats Neuropharmacology 46 2004 254 263
23. J.M. Fine, A.M. Baillargeon, D.B. Renner, N.S. Hoerster, J. Tokarev, S. Colton, A. Pelleg, A. Andrews, K.A. Sparley, K.M. Krogh, W.H. Frey, and L.R. Hanson Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice Exp. Brain Res. 219 2012 381 390
24. L.R. Hanson, J.M. Fine, J.D. Hoekman, T.M. Nguyen, R.B. Burns, P.M. Martinez, J. Pohl, and W.H. Frey II Intranasal delivery of growth differentiation factor 5 to the central nervous system Drug Deliv. 19 2012 149 154
25. M.A. Reger, G.S. Watson, P.S. Green, L.D. Baker, B. Cholerton, M.A. Fishel, S.R. Plymate, M.M. Cherrier, G.D. Schellenberg, W.H. Frey II, and S. Craft Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults J. Alzheimers Dis. 13 2008 323 331
26. S. Türker, E. Onur, and Y. Ozer Nasal route and drug delivery systems Pharm. World Sci. 26 2004 137 142
27. L. Illum Nasal drug delivery: new developments and strategies Drug Discov. Today 7 2002 1184 1189
28. M.T. Vidgren, and H. Kublik Nasal delivery systems and their effect on deposition and absorption Adv. Drug Deliv. Rev. 29 1998 157 177
29. H. Bshara, R. Osman, S. Mansour, and Ael-H. El-Shamy Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats Carbohydr. Polym. 99 2014 297 305
30. F.W. Merkus, J.C. Verhoef, E. Marttin, S.G. Romeijn, P.H. van der Kuy, W.A. Hermens, and N.G. Schipper Cyclodextrins in nasal drug delivery Adv. Drug Deliv. Rev. 36 1999 41 57
31. R. Challa, A. Ahuja, J. Ali, and R.K. Khar Cyclodextrins in drug delivery: an updated review AAPS PharmSciTech 6 2005 (Article 43)
32. S.V. Dhuria, L.R. Hanson, and W.H. Frey II Intranasal delivery to the central nervous system: mechanisms and experimental considerations J. Pharm. Sci. 99 2010 1654 1673
33. V.R. Sinha, A.K. Singla, S. Wadhawan, R. Kaushik, R. Kumria, K. Bansal, and S. Dhawan Chitosan microspheres as a potential carrier for drugs Int. J. Pharm. 274 2004 1 33
34. E. Gavini, G. Spada, G. Rassu, G. Cerri, A. Brundu, M. Cossu, M. Sorrenti, and P. Giunchedi Development of solid nanoparticles based on hydroxypropyl-β-cyclodextrin aimed for the colonic transmucosal delivery of diclofenac sodium J. Pharm. Pharmacol. 63 2011 472 482
35. E. Gavini, G. Rassu, C. Muzzarelli, M. Cossu, and P. Giunchedi Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide Eur. J. Pharm. Biopharm. 68 2008 245 252
36. E. Gavini, G. Rassu, L. Ferraro, S. Beggiato, A. Alhalaweh, S. Velaga, N. Marchetti, P. Bandiera, P. Giunchedi, and A. Dalpiaz Influence of polymeric microcarriers on the in-vivo intranasal uptake of an anti-migraine drug for brain targeting Eur. J. Pharm. Biopharm. 83 2013 174 183
37. K. Felgenhauer Protein size and CSF composition Klin. Wochenschr. 52 1974 1158 1164
38. A. Madu, C. Cioffe, U. Mian, M. Burroughs, E. Tuomanen, M. Mayers, E. Schwartz, and M. Miller Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid Antimicrob. Agents Chemother. 38 1994 2111 2115
39. A. Dalpiaz, N. Marchetti, A. Cavazzini, L. Pasti, S. Velaga, E. Gavini, S. Beggiato, and L. Ferraro Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study J. Chromatogr. B Analyt Technol. Biomed Life Sci. 901 2012 72 78
40. A.V. Simionato, G.D. de Souza, E. Rodrigues-Filho, J. Glick, P. Vouros, and E. Carrilho Tandem mass spectrometry of coprogen and deferoxamine hydroxamic siderophores Rapid Commun. Mass Spectrom. 20 2006 193 199
41. M.P. Van den Berg, S.G. Romeijn, J.C. Verhoef, and F.W. Merkus Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity J. Neurosci. Methods 116 2002 99 107
42. C. Sacchetti, M. Artusi, P. Santi, and P. Colombo Caffeine microparticles for nasal administration obtained by spray drying Int. J. Pharm. 242 2002 335 339
43. R.H. Walters, B. Bhatnagar, S. Tchessalov, K.-I. Izutsu, K. Tsumoto, and S. Ohtake Next generation drying technologies for pharmaceutical applications J. Pharm. Sci. 103 2014 2673 2695
44. K. Inthavong, T. Jiyuan, and A. Goodarz Computational modelling of gas-particle flows with different particle morphology in the human nasal cavity J. Comput. Multiphase Flows 1 2009 57 82
45. D.Q. Craig, P.G. Royall, V.L. Kett, and M.L. Hopton The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems Int. J. Pharm. 179 1999 179 207
46. A. Tesoro, J.S. Leeder, Y. Bentur, J. Klein, M. Freedman, and G. Koren A high-performance liquid chromatographic method for the measurement of deferoxamine in body fluids Ther. Drug Monit. 11 1989 463 470
47. P.R. Dragsten, P.E. Hallaway, G.J. Hanson, A.E. Berger, B. Bernard, and B.E. Hedlund First human studies with a high-molecular-weight iron chelator J. Lab. Clin. Med. 135 2000 57 65
48. A. Dalpiaz, E. Gavini, G. Colombo, P. Russo, F. Bortolotti, L. Ferraro, S. Tanganelli, A. Scatturin, E. Menegatti, and P. Giunchedi Brain uptake of an antiischemic agent by nasal administration of microparticles J. Pharm. Sci. 97 2008 4889 4903
49. E. Gavini, G. Rassu, L. Ferraro, A. Generosi, J.V. Rau, A. Brunetti, P. Giunchedi, and A. Dalpiaz Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres J. Pharm. Sci. 100 2011 1488 1502
50. W. Ziolkowski, M. Szkatula, A. Nurczyk, T. Wakabayashi, J.J. Kaczor, R.A. Olek, N. Knap, J. Antosiewicz, M.R. Wieckowski, and M. Wozniak Methyl-beta-cyclodextrin induces mitochondrial cholesterol depletion and alters the mitochondrial structure and bioenergetics FEBS Lett. 584 2010 4606 4610
51. S.T. Lim, B. Forbes, D.J. Berry, G.P. Martin, and M.B. Brown In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits Int. J. Pharm. 231 2002 73 82
52. L. Illum Nasal drug delivery - possibilities, problems and solutions J. Control. Release 87 2003 187 198
53. L. Illum Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56 2004 3 17
54. A. Mistry, S. Stolnik, and L. Illum Nanoparticles for direct nose-to-brain delivery of drugs Int. J. Pharm. 379 2009 146 157